Cost-Effectiveness Analysis of Patiromer in Combination with Renin –Angiotensin–Aldosterone System Inhibitors for Chronic Kidney Disease in Sweden

ConclusionsThe results indicate that patiromer may demonstrate value for money in Swedish patients with stage 3 –4 CKD, by enabling RAASi treatment. However, there is a considerable degree of uncertainty.
Source: PharmacoEconomics - Category: Health Management Source Type: research